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Genetic testing in ALS
A survey of current practices
ABSTRACT
Objective: To determine the degree of consensus among clinicians on the clinical use of genetic
testing in amyotrophic lateral sclerosis (ALS) and the factors that determine decision-making.
Methods: ALS researchers worldwide were invited to participate in a detailed online survey to
determine their attitudes and practices relating to genetic testing.
Results: Responses from 167 clinicians from 21 different countries were analyzed. The majority
of respondents (73.3%) do not consider that there is a consensus definition of familial ALS
(FALS). Fifty-seven percent consider a family history of frontotemporal dementia and 48.5%
the presence of a known ALS genetic mutation as sufficient for a diagnosis of FALS. Most re-
spondents (90.2%) offer genetic testing to patients they define as having FALS and 49.4% to
patients with sporadic ALS. Four main genes (SOD1, C9orf72, TARDBP, and FUS) are commonly
tested. A total of 55.2% of respondents would seek genetic testing if they had personally
received a diagnosis of ALS. Forty-two percent never offer presymptomatic testing to family
members of patients with FALS. Responses varied between ALS specialists and nonspecialists
and based on the number of new patients seen per year.
Conclusions: There is a lack of consensus among clinicians as to the definition of FALS. Substan-
tial variation exists in attitude and practices related to genetic testing of patients and presymp-
tomatic testing of their relatives across geographic regions and between experienced specialists
in ALS and nonspecialists. Neurology® 2017;88:1–9
GLOSSARY
ALS5 amyotrophic lateral sclerosis; FALS5 familial amyotrophic lateral sclerosis; FTD5 frontotemporal dementia; SALS5
sporadic amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis (ALS) is categorized into familial (FALS) and sporadic (SALS)
forms. However, the recognition of FALS is limited by incomplete penetrance of disease-
causing mutations and variable family size, which can result in apparently sporadic presentation
of familial disease.1,2 Heritability estimates for SALS are high,3–5 relatives of patients with SALS
are at increased risk,6 and mutations known to cause FALS have frequently been observed in
apparently sporadic cases of ALS.7 Familial forms of the condition are often characterized by
reduced penetrance and genetic pleiotropy, and there is evidence of both oligogenic and poly-
genic inheritance in apparently sporadic disease.8 In addition, ancestral origin is important, with
variation in the frequency of ALS genes in different patient populations.7,9–11
Increasing knowledge of the genetic architecture of ALS suggests that the majority of future
discoveries are likely to involve a multitude of rare, de novo, or low-effect risk variants and
disease-causing mutations.12 Given these complexities, decisions by clinicians as to whom to
refer for genetic testing and which genes to test require detailed knowledge of a rapidly changing
genetic landscape. Published consensus guidelines from 2012 have quickly been superseded by
new findings13 and formal provision of genetic testing for those who have a first- or second-degree
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relative with ALS or frontotemporal dementia
(FTD) is now recommended,14 as is a consid-
eration for genetic testing of apparently
sporadic disease, and recognition that each
ancestral population will have a different
genetic profile. Guidelines for presymptomatic
testing in a research setting that includes pre-
decision, pretest, and posttest counseling have
also been published.15
Using these existing recommendations, we
have evaluated the international consensus on
the use and perceived value of genetic testing
in ALS, and have assessed the factors that
determine the extent to which ALS clinicians
recommend genetic testing in a clinical setting.
METHODS A questionnaire on attitudes toward genetic test-
ing for ALS was designed following consultation with neurolo-
gists specializing in ALS (supplemental data at Neurology.org).
Participants were asked to respond to questions about their
opinions of the definition of FALS, their use of genetic testing
in clinical practice for patients and presymptomatic family
members, and their own personal preference for testing if they
were a patient with ALS. The known ALS genes included in the
survey were SOD1, C9orf72, TARDBP, FUS, ANG, VABP,
SETX, DCTN1, VCP, UBQLN2, PFN1, and ATXN2. These
were selected as being the most likely to be tested based on
their importance and their association with specific ancestral
populations and clinical phenotype. Demographics information
was collected to allow comparison of the opinions of clinicians
from different countries and with different levels of experience.
Twenty-one questions were uploaded to Survey Monkey
(surveymonkey.com) and the link was circulated by members
of ALS networks from Europe (the European Network for the
Cure of ALS), the United States (the Northeast ALS
Consortium), Canada (the Canadian ALS Research Network),
Australia, Japan, and South America. Statistical analyses were
performed using R version 3.0.2 using Fisher exact test or
linear regression.
RESULTS Demographics. A total of 167 clinicians
(116 male, 51 female) from 21 countries responded
to the survey. Respondents were mainly neurologists
(86.8%) and trainee neurologists (10.8%). Most were
from academic university hospitals (85.6%), with the
remainder working at general hospitals (9.6%) or pri-
vate hospitals and clinics (4.8%). A total of 50.9% of
those questioned see more than 30 new patients with
ALS each year, 9.6% see 21–30, and the remainder
(39.5%) see fewer than 20. The majority stated that
they have a special interest in ALS (83.2%) and of
those 23.0% had been specializing in the field for
more than 20 years, 34.5% for 10–20 years, and
42.5% for less than 10 years.
Definition of FALS. The majority of those surveyed
(73.3%) did not consider that there is a standard def-
inition among neurologists for FALS (figure 1A).
This proportion did not differ significantly when con-
sidering broad geographic regions (the Americas, Eu-
rope, and Asia-Pacific; p 5 0.17, Fisher exact test) or
individual countries (p 5 0.66).
Respondents were provided with a list of FALS
definitions and asked to select all those that fitted
their definition in clinical practice (figure 1B). As
the stringency of the FALS definition increased
(i.e., as the family members with ALS became more
Figure 1 Definition of familial amyotrophic lateral sclerosis (FALS)
(A) Country-specific variation in opinion on the existence of a standard definition for FALS. (B) FALS definitions used by respondents. Within amyotrophic
lateral sclerosis (ALS) or frontotemporal dementia (FTD) disease categories, choice of a lower-stringency definition automatically meant higher stringency
definitions were also selected. SALS 5 sporadic amyotrophic lateral sclerosis.
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closely related and increased in number), so did the
number of respondents who accepted that definition.
A total of 48.5% of respondents considered testing
positive for a known ALS gene to be sufficient to meet
the criteria for FALS, and the presence of a family
history of FTD was considered relevant by 57% of
respondents. Respondents who identified themselves
as having a special interest in ALS were more likely to
use less strict definitions of FALS, and for example,
include patients with 1 first- or 1 second-degree rel-
ative with ALS in their definition (73.38% vs
39.29%, p 5 7.7 3 1024, Fisher exact test). Simi-
larly, 42% of those with a special interest, but only
14% of nonspecialists, agreed that the presence of
a first- or second-degree relative with FTD met the
criteria for FALS (p 5 5.1 3 1023, Fisher exact test).
Those who see more than 30 new patients with ALS
per year were significantly more likely than those who
see fewer to define this case as FALS (52.9% vs
22.0% [p 5 5.6 3 1025]). Fifty-two percent of spe-
cialists use detection of a known gene in a sporadic
case as one of their definitions of FALS, compared to
28.57% of nonspecialists (p5 23 1022, Fisher exact
test). Those with more than 15 years’ experience and
those who see more than 30 new patients a year were
more likely to include this in their definition of
FALS compared to those who have less experience
(p 5 6.1 3 1023 and p 5 0.02, respectively).
Use of genetic testing in clinical practice. The majority
of respondents (90.2%) stated that they offer diagnos-
tic testing for patients who meet their definition of
FALS, while 49.4% of respondents stated that they
offer genetic testing to patients with no known
family history of ALS (figure 2, A and B). Those with
a special interest in ALS were significantly more like-
ly to offer genetic testing, both in cases of FALS (p 5
1.8 3 1024) and SALS (p 5 9.1 3 1025). Experi-
enced ALS specialists (those specializing in ALS for
more than 15 years) were not significantly different
from less experienced specialists in their decision to
test patients with positive or negative family histories
of ALS (p 5 1.0 and 0.49, respectively, Fisher exact
test). However, respondents who see more than 30
new patients with ALS per year were significantly
more likely to offer diagnostic genetic testing to
patients with FALS and SALS (p 5 1.2 3 1024 and
2.6 3 1025, respectively, Fisher exact test). Respond-
ents’ likelihood of recommending genetic testing was
strongly influenced by the number and degree of rel-
atives with ALS (figure 2C). When presented with
a list of reasons for not offering testing for either SALS
Figure 2 Genetic testing of patients with and without a family history of amyotrophic lateral sclerosis (ALS)
(A) Diagnostic genetic testing offered to patients with a family history of ALS (yes/no). (B) Diagnostic genetic testing offered to patients with no known family
history of ALS (yes/no). (C) Genetic testing recommended to indicated proband (yes/no).
Neurology 88 March 7, 2017 3
or FALS, the most common answer was the absence of
any change in treatment plan (42.4%), then the cost
of testing (37.9%), inadequate access to genetic coun-
seling (25.8%), a belief that ALS genetics are not well
enough understood in general (16.7%), or by the
clinical team providing care (15.2%).
Although there was some regional variation in the
gene panel tested by respondents, there was a general
consensus in the choice of testing for 4 main ALS
genes (figure 3A): SOD1 (68.3% of respondents test),
C9orf72 (63.5%), TARDBP (43.1%), and FUS
(43.7%). Other known genes included in the survey
received lower priority, and correlated with the num-
ber of publications that associate the gene with ALS
(SOD1 and TARDBP excluded; figure 3B; r25 0.98;
p 5 2 3 1028) and the number of mutations that
have been reported for the gene in the ALS online
genetics database16 (C9orf72 and SOD1 excluded;
figure 3B; r25 0.86; p5 13 1024). Genetic testing
for C9orf72 was lower in Japan, but higher than ex-
pected given that this variant is rare in the Asian
population (30% of Japanese respondents would test
this gene vs 67% of non-Japanese respondents). Fac-
tors that influenced the selection of genes included
the presence of a family history of FTD in addition to
ALS (68.3%), the phenotype of the patient (59.3%),
geography and ethnicity (21.6%), and in a minority,
the advice of a specialist genetic counselor (12.0%).
Personal preference and consistency. The majority of re-
spondents demonstrated consistency in their re-
sponses across various scenarios. Over half of those
who responded stated that they would seek genetic
testing if they had personally received a diagnosis of
ALS (55.2%). While there was no significant differ-
ence between broad geographic regions, there was
Figure 3 Choice of genes in genetic testing
(A) Heat map of genes tested by respondents broken down by country. (B) The number of publications in amyotrophic lateral sclerosis (ALS) research con-
cerning each gene as a function of the number of respondents who test for that gene (top) and the number of mutations reported in the ALS online database
(ALSoD) for each gene as a function of the number of respondents who test for that gene (bottom).
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a considerable variation across different countries
(p5 3.03 1023, Fisher exact test). In some countries
(for example, Ireland, United Kingdom, Japan, and
United States), the majority of respondents stated
that they would not seek testing or would test only
for research purposes (figure 4A). Respondents’ per-
sonal preferences for testing were also compared to
answers they provided regarding their professional
practice: 11.4% stated that they would offer testing
to a patient with FALS (pedigree 1 in figures 2 and 4)
but would only test themselves for research purposes
or not at all, while 1.8% of respondents stated that
they would test themselves but would not advise their
patients to undergo testing. For SALS, these propor-
tions were 28.7% and 8.2%, respectively.
Presymptomatic testing. Forty-eight percent of respond-
ents never offer presymptomatic testing to family
members of patients with FALS (figure 5A). These
proportions differed by geographic region (p 5
0.015, Fisher exact test), with respondents from
Asia-Pacific stating never 1.8 times as frequently as
those from the Americas (73.3% vs 40.5%) and 1.6
times as frequently as Europeans (47.2%). Specialists
in ALS were significantly more likely to offer
presymptomatic testing sometimes or always
compared to nonspecialists (59.5% vs 14.8%, p 5
2.83 3 1025, Fisher exact test). Experienced ALS
specialists (.15 years) were not significantly more
likely than less experienced specialists to offer
presymptomatic genetic testing to unaffected family
members of patients with ALS (p 5 1.0, Fisher exact
test) but respondents who see more than 30 new
patients with ALS per year were significantly more
likely to offer presymptomatic testing (p 5 1.7 3
1027, Fisher exact test). Of the list of reasons
presented to respondents for not testing, the most
common selected was that no presymptomatic
treatment is possible (51.9%, figure 5B), while the
most common reason for offering presymptomatic
testing was the belief that family members have
a right to know (82.3%, figure 5B).
The answers of the respondents were used to com-
pare whether they offer presymptomatic testing to pa-
tients and whether they would recommend testing to
at-risk members of their own family. While most
Figure 4 Number of respondents who would seek genetic testing if diagnosed with amyotrophic lateral sclerosis (ALS)
(A) Would seek genetic testing (yes/no). (B) Would seek genetic testing if the indicated proband (yes/no).
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respondents were consistent, almost one-fifth of all re-
spondents stated that they would offer presymptomatic
testing to patients’ families but would not recommend
it to their own family, and 13% stated that they would
recommend testing in their own family but would not
recommend this to their patients.
DISCUSSION The true frequency of FALS has not
been established, partly because the definition remains
unclear. A meta-analysis of population-based registers
undertaken prior to the discovery of the C9orf72
repeat expansion suggested a FALS rate of 5.1%.17
However, a subsequent detailed family aggregation
study, including cases identified through death
certification and review of medical notes, suggests
that 16% of patients have at least one other family
member with ALS and 14% have a first-, second-, or
third-degree relative with ALS.18 An audit of the Irish
ALS register for patients diagnosed between 2013 and
2015 provides a rate of FALS of 16.61% for patients
with 1 first- or 1 second-degree relative with ALS.
This increases to 19.38% if first- or second-degree
relatives with FTD are included, and is reduced to
3.81% if restricted only to those who have 2 or
more first-degree relatives with ALS, demonstrating
the range in the estimated rate of FALS, depending
on the definition used, and the amount of information
available (A. Vajda, unpublished data, 2016).
In the absence of a formal and evidence-based def-
inition of FALS, it is difficult for clinicians to provide
clear advice to patients and their families with ALS.
This observation is reflected in our survey, in which
73.3% of respondents stated that there is no consen-
sus as to the definition of FALS.
As would be expected, as the number of family
members with ALS and their relatedness to the
patient in question increased, so did the number of
all respondents who accepted that definition of FALS.
Compared to previous studies, a higher portion of re-
spondents now consider the presence of a family his-
tory of FTD in the diagnosis of FALS, reflecting the
growing recognition of the clinical overlap between
the 2 disorders. Specialists and those who see more
than 30 new patients with ALS per year were more
inclusive in their diagnosis of FALS, with a higher
likelihood of including those with a family history
of FTD or those who appear sporadic by family his-
tory but test positive for a known ALS gene.
In terms of the use of diagnostic testing, most re-
spondents offer genetic testing for 4 main genes
(SOD1, C9orf72, TARDBP, and FUS) to those pa-
tients meeting their previously defined criterion for
FALS, which is consistent with recommendations by
the ITALSGEN consortium.14 Although we detected
regional variation in the choice of genes, as would be
expected given the importance of ancestral and geo-
graphic variation in gene frequencies, the rates of
testing did not always reflect the prevalence of
disease-causing variants. For example, 30% of re-
spondents from Japan reported testing for C9orf72
Figure 5 Respondents’ opinions on presymptomatic testing
(A) Would offer presymptomatic testing to family members of patients with known (FALS) (yes/no). (B) Factors that would determine the decision to offer
presymptomatic testing to family members of patients with known familial amyotrophic lateral sclerosis (FALS).
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variants, despite this gene not contributing signifi-
cantly to ALS in Japan,19 and 75% of Dutch respond-
ents test for SOD1, which was not significantly
different from the rate of testing in non-Dutch re-
spondents (68%; p 5 1.0, Fisher exact test), despite
published evidence of low prevalence of SOD1
disease-causing variants in the Netherlands.9
Our current knowledge of ALS genetics largely
comes from the study of ancestral European (Europe,
United States, Canada, and Australia) and East Asian
populations.14 The frequency of known genes has not
been established in African populations,20 and little is
known about the population-based frequencies of
ALS in the admixed populations of South America,
the Middle East, or India. A number of genetically
isolated populations with relatively homogenous
genetic backgrounds have been reported, with strong
evidence of founder effects in some regions. For
example, more than 40% of Sardinian patients with
ALS have a mutation in a known ALS gene (TDP43
or C9orf72).21 Similarly, Northern Finland exhibits
high rates of C9orf72 repeat expansions and Northern
Sweden has high rates of SOD1 mutations.22 Recog-
nition of the presence of a likely founder within
a region could inform both genetic counseling and
testing. However, it must also be noted that there is
evidence of oligogenic inheritance in ALS, and that
testing of a single gene variant in familial ALS could
provide inaccurate information.23
We found that decisions surrounding genetic test-
ing were less consistent in the case of apparently spo-
radic patients, with an almost even split between
those respondents who reported that they sometimes
offer and those who never offer diagnostic testing. Fac-
tors that determined the decision to offer testing
included whether the neurologists were specialists in
ALS and the number of patients seen per year, requests
by patients, and recognition that some disease-
associated variants are incompletely penetrant. How
respondents address the implications of finding a path-
ogenic gene variant in non-FALS patients, and whether
all respondents seek the advice and support of genetic
counselors prior to diagnostic testing, was not ad-
dressed by our questionnaire. However, given that only
12% of all respondents reported that they select genes
for testing following consultation with a counselor, it is
likely that many ALS clinics do not have access to or
utilize expert genetic counseling services, and it may
also be that some patients are tested without full dis-
cussion with a qualified counselor as to the implica-
tions of a genetic diagnosis.
Another important factor in determining whether
testing is offered may be regional variation in access
to genetic testing through the health system and the
reimbursement policies of insurance companies. The
American ALS Association has estimated that the cost
of testing for all known FALS genes is in the region of
$6,000.24 While the implications of cost were not as-
sessed by our study, there is considerable variation in
the attitudes of insurance companies and health serv-
ices with respect to funding the costs of counseling and
testing. Counseling and testing may not be covered by
some US-based insurance companies, while in regions
with socialized health systems such as Italy, the process
is funded if recommended by a specialist.14 This vari-
ation could have affected our findings.
Respondents were also divided regarding testing of
presymptomatic family members of patients with
FALS. Specialists in ALS differed significantly in their
response from nonspecialists. In addition, a geo-
graphic variation was noted, with respondents from
the United States and Europe being more likely to
offer presymptomatic testing compared with their
counterparts in Australia and Japan. The right to
know was the commonest reason provided by re-
spondents who offered presymptomatic testing, and
a view that the implications of carrying a known var-
iant are not known, and therefore cannot be reliably
discussed with those wishing to undergo presymp-
tomatic testing, was the commonest reason reported
by respondents who do not routinely offer presymp-
tomatic testing. An updated set of guidelines for pro-
viding presymptomatic genetic counseling and testing
to people at high genetic risk for developing ALS will
be of value to practitioners engaging with families
with known ALS-causing variants.
A substantial number of respondents (44.8%)
would not seek genetic testing if they had personally
received a diagnosis of ALS. In general, respondents
to this survey were consistent with respect to how
they would approach testing of themselves and their
family members, compared to what they recommend
to their patients, although a minority were discor-
dant. This discordance was not associated with geo-
graphic location, suggesting that it was driven by
personal attributes of the clinicians rather than cul-
tural determinants.
The complexity of ALS genetics renders the character-
ization of FALS problematic, and the provision of genetic
counseling is limited by our current knowledge base. The
pathogenicity of many reported gene variants in ALS re-
mains unproven, and there is strong evidence to suggest
that at least some are not disease-causing.25 The likely
presence of oligogenic inheritance, genetic pleiotropy,
and the absence of a clear phenotype/genotype correla-
tion for many gene variants adds to the complexity. For
example, SOD1, the first gene found to be associated
with ALS, has over 160 reported mutations associated
with phentotypes that range from a rapidly progress-
ing form of the disease to a much milder, slowly
progressing form.26,27 In the case of the C9orf72
repeat expansion, healthy individuals typically have
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10 or fewer repeats, and patients with ALS or FTD
associated with this variant have between 30 and
many thousands of repeats. However, an intermediate
repeat number of 20–30 has been identified in both
patients and controls, and further study is required to
better understand the phenotype/genotype correla-
tion for this mutation.28,29
Taken together, our data indicate an absence of
consensus regarding the definition of FALS, and in-
consistencies in the application of recent guidelines
in the provision of genetic counseling and use of
genetic testing in ALS. While this is not surprising
given the complexity of ALS genetics, we detected sig-
nificant differences in practice across geographic re-
gions, and between specialists’ experience in
managing many patients with ALS and those who
follow relatively few patients, or do not have a special
interest in the disease. It is likely that the observed
variations in practice reflect not only differences in
cultural attitudes to genetic testing, but also the level
of expertise of the practitioner, and the availability of
resources within the health care system of the country.
Our data are limited by the study design. As the survey
was disseminated by various networks, we cannot accu-
rately calculate the response rate. Furthermore, the
number of respondents (167) may be a limitation,
given their spread over 21 countries. However, while
the possibility of bias in response cannot be excluded,
we have no reason to consider that the views of the
respondents, many of whom described themselves as
ALS specialists, were not representative.
These data suggest that the clinical application of
genetic testing in symptomatic patients is not always
evidence-based, and that genetic counseling of patients
and their families does not occur routinely as a standard
of care in all instances. Presymptomatic testing may
sometimes occur with limited recognition of the pres-
ence of genetic pleiotropy and oligogenic inheritance.
These findings suggest the need for evidence-based
and consensus guidelines as to the most appropriate
utilization of diagnostic and presymptomatic genetic
testing in routine clinical management of patients with
ALS and their extended families.
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